Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Levis
D Small

Leukemia

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Leukemia|September 13, 2003
FLT3: ITDoes matter in leukemiaM Levis, D Small
Leukemia|June 9, 2006
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent mannerP Brown, M Levis, E McIntyre, et al.
Leukemia|October 3, 2002
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitorK-F Tse, J Allebach, M Levis, et al.
Leukemia|August 4, 2012
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitorsA B Williams, B Nguyen, L Li, et al.
Leukemia|October 6, 2000
Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformationK F Tse, G Mukherjee, D Small
Leukemia|December 22, 2015
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cellsE Chang, S Ganguly, T Rajkhowa, et al.
Leukemia|October 18, 2016
DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cellsM Wu, M Hamaker, L Li, et al.
Leukemia|July 18, 2001
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitorK F Tse, E Novelli, C I Civin, et al.
Leukemia|November 20, 2013
Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinibC Schaab, F S Oppermann, M Klammer, et al.
Leukemia|February 3, 2007
Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative diseaseB R Baldwin, L Li, K-F Tse, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Leukemia|September 13, 2003
FLT3: ITDoes matter in leukemiaM Levis, D Small
Leukemia|June 9, 2006
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent mannerP Brown, M Levis, E McIntyre, et al.
Leukemia|October 3, 2002
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitorK-F Tse, J Allebach, M Levis, et al.
Leukemia|August 4, 2012
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitorsA B Williams, B Nguyen, L Li, et al.
Leukemia|October 6, 2000
Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformationK F Tse, G Mukherjee, D Small
Leukemia|December 22, 2015
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cellsE Chang, S Ganguly, T Rajkhowa, et al.
Leukemia|October 18, 2016
DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cellsM Wu, M Hamaker, L Li, et al.
Leukemia|July 18, 2001
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitorK F Tse, E Novelli, C I Civin, et al.
Leukemia|November 20, 2013
Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinibC Schaab, F S Oppermann, M Klammer, et al.
Leukemia|February 3, 2007
Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative diseaseB R Baldwin, L Li, K-F Tse, et al.
Pageof 2